Published in Mol Oncol on December 28, 2007
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion. J Invest Dermatol (2012) 1.63
Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56
BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. Appl Immunohistochem Mol Morphol (2015) 1.47
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis (2010) 1.25
Genetic risk factors for melanoma. Hum Genet (2009) 1.21
Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. J Invest Dermatol (2009) 1.16
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer (2012) 1.07
Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer (2010) 1.00
Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. J Invest Dermatol (2013) 1.00
Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol (2012) 0.97
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer (2014) 0.93
Ameloblastoma: A Review of Recent Molecular Pathogenetic Discoveries. Biomark Cancer (2015) 0.93
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther (2014) 0.91
Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med (2013) 0.87
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget (2017) 0.85
Comparison of Three BRAF Mutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples. Korean J Pathol (2013) 0.85
Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases (2011) 0.85
Conserved expression signatures between medaka and human pigment cell tumors. PLoS One (2012) 0.84
The functional relevance of somatic synonymous mutations in melanoma and other cancers. Pigment Cell Melanoma Res (2015) 0.84
Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med (2010) 0.84
Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer (2014) 0.84
The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma. BMC Cancer (2014) 0.83
Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells. Am J Surg (2012) 0.83
Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget (2014) 0.83
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clin Exp Metastasis (2013) 0.82
The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol (2012) 0.82
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. Tumour Biol (2014) 0.82
Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Rep (2012) 0.82
BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res (2015) 0.81
Molecular bases of cutaneous and uveal melanomas. Patholog Res Int (2011) 0.81
Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment. World J Exp Med (2015) 0.80
Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract (2010) 0.80
In situ Protein Detection for Companion Diagnostics. Front Oncol (2013) 0.80
Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol (2012) 0.79
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. Ecancermedicalscience (2015) 0.79
Low mutational burden of eight genes involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 pathways in female genital tract primary melanomas. Biomed Res Int (2015) 0.78
Melanoma and the Unfolded Protein Response. Cancers (Basel) (2016) 0.78
BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res (2015) 0.78
Phytochemicals for the Management of Melanoma. Mini Rev Med Chem (2016) 0.77
Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett (2017) 0.75
Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. Oncotarget (2017) 0.75
Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts. Int J Oncol (2015) 0.75
Oral malignant melanoma: A report of two cases with BRAF molecular analysis. Oncol Lett (2014) 0.75
Ultraviolet Radiation-Induced Cytogenetic Damage in White, Hispanic and Black Skin Melanocytes: A Risk for Cutaneous Melanoma. Cancers (Basel) (2015) 0.75
Synthetic lethality: emerging targets and opportunities in melanoma. Pigment Cell Melanoma Res (2017) 0.75
TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma. Oncol Lett (2016) 0.75
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Med J (2017) 0.75
KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth. Oncogene (2017) 0.75
Focus on cutaneous and uveal melanoma specificities. Genes Dev (2017) 0.75
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC Cancer (2017) 0.75
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet (2008) 3.90
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res (2006) 3.32
A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst (2003) 3.29
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res (2003) 2.72
Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst (2002) 2.70
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet (2011) 2.24
Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem (2002) 2.20
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol (2010) 1.93
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet (2008) 1.84
Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst (2003) 1.74
A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer (2005) 1.70
IRF4 variants have age-specific effects on nevus count and predispose to melanoma. Am J Hum Genet (2010) 1.55
Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol (2002) 1.54
Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res (2002) 1.52
Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers. BMC Psychiatry (2010) 1.50
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet (2011) 1.46
An integrated health and social care organisation in Sweden: creation and structure of a unique local public health and social care system. Health Policy (2010) 1.41
[Nevus or malignant melanoma? Correct diagnostic competence results in lower costs]. Lakartidningen (2008) 1.40
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials (2014) 1.39
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer (2005) 1.37
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol (2008) 1.28
Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res (2006) 1.26
A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res (2013) 1.17
Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. J Invest Dermatol (2009) 1.16
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin Chem (2004) 1.13
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst (2009) 1.11
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer (2014) 1.10
Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci (2002) 1.08
KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res (2011) 1.08
Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin Chem (2002) 1.07
Suffering in silence: a qualitative study of second victims of adverse events. BMJ Qual Saf (2013) 1.06
Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer (2009) 1.05
Implementing organisation and management innovations in Swedish healthcare: lessons from a comparison of 12 cases. J Health Organ Manag (2012) 1.05
Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. Acta Oncol (2002) 1.04
Genetic testing for melanoma. Lancet Oncol (2002) 1.03
Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet (2003) 1.03
Hereditary uveal melanoma: a report of a germline mutation in BAP1. Genes Chromosomes Cancer (2013) 1.03
Melanoma cells produce multiple laminin isoforms and strongly migrate on α5 laminin(s) via several integrin receptors. Exp Cell Res (2010) 1.01
Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics (2013) 0.99
Skin cancer identification using multifrequency electrical impedance--a potential screening tool. IEEE Trans Biomed Eng (2004) 0.98
Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin Cancer Res (2005) 0.98
Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res (2012) 0.98
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res (2013) 0.97
Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer (2004) 0.97
High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. J Invest Dermatol (2010) 0.95
Interobserver variability of histopathological prognostic parameters in cutaneous malignant melanoma: impact on patient management. Acta Derm Venereol (2013) 0.94
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. Cancer Immunol Immunother (2008) 0.94
Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol (2008) 0.94
Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res (2004) 0.94
The Stockholm declaration. Mol Oncol (2008) 0.94
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters. Pigment Cell Melanoma Res (2008) 0.92
Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure: a retrospective population-based study. Melanoma Res (2015) 0.90
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother (2014) 0.88
Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res (2004) 0.88
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. Int J Cancer (2014) 0.87
Cancer of the skin: a forgotten problem in Europe. Ann Oncol (2004) 0.86
Family members' perceptions of genetic testing for malignant melanoma--a prospective interview study. Eur J Oncol Nurs (2009) 0.86
Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci (2003) 0.86
Radiotherapy and cancer care in Sweden. Acta Oncol (2003) 0.85
Pressure transduction and fluid evacuation during conventional negative pressure wound therapy of the open abdomen and NPWT using a protective disc over the intestines. BMC Surg (2012) 0.85
Inherited variation in the PARP1 gene and survival from melanoma. Int J Cancer (2014) 0.85
Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. Int J Cancer (2014) 0.84
An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res (2013) 0.84
HSP60 predicts survival in advanced serous ovarian cancer. Int J Gynecol Cancer (2013) 0.84
Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program. J Clin Oncol (2007) 0.83
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci (2013) 0.83
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res (2006) 0.83
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines. Melanoma Res (2013) 0.83
High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope (2004) 0.83
Tobacco: deadly in any form or disguise. Lancet (2006) 0.83
Agile, a guiding principle for health care improvement? Int J Health Care Qual Assur (2015) 0.83
Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. Hum Pathol (2004) 0.82
Surgical treatment of skeletal metastases in 31 melanoma patients. Acta Orthop Belg (2012) 0.82
Effect of primary site on prognosis in patients with cutaneous malignant melanoma. A study using a new model to analyse anatomical locations. Melanoma Res (2005) 0.82